Bora Biologics has executed over 200 cGMP batches to date, including more than 60 batches dedicated specifically to commercial supply programs. This extensive experience addresses a critical challenge in modern medicine: the need for reliable, high-speed diagnostic tools that can keep pace with an
Rising demand for genomic research across Europe is pushing the regional automated nucleic acid extraction market toward a projected valuation of three billion dollars by 2035. This significant shift marks a definitive departure from traditional manual sample preparation methods that have long
The United Kingdom's healthcare ecosystem, currently valued at approximately £345 billion, is undergoing a period of intense transformation that challenges traditional operational models. This landscape represents a sophisticated, multi-layered environment that now accounts for roughly 11.4% of the
Maternal health and newborn outcomes show no significant differences between those who use non-invasive genetic screening and those who rely on conventional grading. This finding emerges from a pivotal moment in reproductive medicine, where the promise of sophisticated genomic tools often outpaces
Screening for high-risk contraindications such as Medullary Thyroid Cancer is a non-negotiable step in the initial intake process for any patient. This rigorous medical standard has become the bedrock of the weight management industry in 2026, as the United States continues to grapple with a
The competitive gap between Europe and regions like the United States and China is widening due to administrative delays that slow the deployment of multinational clinical studies. While the European Union possesses world-class healthcare infrastructure, the logistical reality for biotech
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32